atraid Antibody

What is ATRAID protein and what cellular functions does it regulate?

ATRAID, also known as APR3, p18, or C2orf28, is a protein encoded by the ATRAID gene (Gene ID: 51374). This protein plays several critical roles in cellular function, primarily promoting osteoblast cell differentiation and terminal mineralization. ATRAID is also involved in cell cycle regulation, specifically by inducing cell cycle arrest through the inhibition of CCND1 expression within the all-trans-retinoic acid (ATRA) signaling pathway . The protein has a calculated molecular weight of approximately 25 kDa based on its 229 amino acid sequence, though observed molecular weights in experimental conditions typically range between 28-35 kDa depending on post-translational modifications and the specific isoform detected .

Understanding ATRAID's functions provides important insights into bone development pathways and cell cycle control mechanisms, making it a significant target for research in developmental biology, cancer research, and regenerative medicine applications.

What are the known isoforms of ATRAID protein and how does the antibody detect them?

The ATRAID protein exists in three distinct isoforms with molecular weights of approximately:

• 20-24 kDa

• 16-19 kDa

• 28-30 kDa

The Proteintech ATRAID antibody (25548-1-AP) has been specifically developed to recognize all three isoforms, making it particularly valuable for comprehensive studies of ATRAID expression . This polyclonal antibody was developed using an ATRAID fusion protein (specifically, Ag22168) as the immunogen, which enables its broad detection capabilities across the different isoforms .

When performing Western blot experiments with this antibody, researchers should expect to observe bands at these various molecular weights depending on the tissue or cell type being examined. The presence of multiple bands is not indicative of non-specific binding, but rather the antibody's intended ability to detect the different ATRAID isoforms that may be expressed at varying levels across different biological samples.

What applications is the ATRAID antibody validated for?

The ATRAID antibody (25548-1-AP) has been validated for the following applications:

• Western Blot (WB): The primary application with demonstrated effectiveness in detecting ATRAID protein in various sample types.

• Enzyme-Linked Immunosorbent Assay (ELISA): Validated for quantitative determination of ATRAID in solution-based samples .

This antibody has shown positive Western blot detection in several sample types, including:

• Mouse brain tissue

• HEK-293 cells

• Mouse kidney tissue

What is the optimal dilution range for ATRAID antibody in Western Blot applications?

The recommended dilution range for the ATRAID antibody (25548-1-AP) in Western Blot applications is 1:200 to 1:1000 . This relatively broad range allows researchers to optimize the concentration based on their specific experimental conditions, sample type, and detection method.

It's important to note that the optimal dilution may be sample-dependent, and researchers are advised to perform a dilution series during initial experiments to determine the optimal concentration for their specific experimental setup. Factors that may influence the optimal dilution include:

• The abundance of the target protein in your sample

• The detection method being used (chemiluminescence, fluorescence, etc.)

• The type of membrane

• The blocking agent

• The specific tissue or cell type being analyzed

As a methodological best practice, researchers should begin with a middle dilution (approximately 1:500) and adjust accordingly based on signal strength and background levels in preliminary experiments .

What types of samples show reactivity with the ATRAID antibody?

The ATRAID antibody (25548-1-AP) has demonstrated reactivity with samples from both human and mouse origins . Specifically, positive Western blot results have been documented with:

• Human cell lines: HEK-293 cells have shown clear reactivity

• Mouse tissues: Both brain and kidney tissues from mice have demonstrated positive signals

The cross-species reactivity between human and mouse samples indicates conservation of the epitope recognized by this antibody between these species, making it versatile for comparative studies . This cross-reactivity is particularly valuable for researchers conducting translational research where findings in mouse models need to be validated in human samples or cell lines.

How can researchers optimize Western Blot protocols for detecting all three isoforms of ATRAID?

Detecting all three isoforms of ATRAID (20-24 kDa, 16-19 kDa, and 28-30 kDa) in a single Western blot experiment requires careful optimization of several parameters:

Gel Percentage Selection:
Use a gradient gel (4-20%) or a medium percentage (10-12%) polyacrylamide gel to ensure adequate separation of the different molecular weight isoforms. Lower percentage gels (8%) may not provide sufficient resolution between the 16-19 kDa and 20-24 kDa isoforms, while higher percentage gels may make it difficult to transfer the larger 28-30 kDa isoform efficiently .

Transfer Conditions:
Implement a dual transfer protocol: begin with standard transfer conditions (100V for 60 minutes) followed by an extended transfer period at lower voltage (30V for 30-60 minutes) to ensure complete transfer of all molecular weight ranges.

Sample Preparation:

• Utilize a protease inhibitor cocktail during sample preparation to prevent degradation of the different isoforms

• Compare multiple lysis buffers (RIPA, NP-40, etc.) in preliminary experiments to determine optimal extraction efficiency for all isoforms

• Consider running both reduced and non-reduced samples in parallel to examine potential differences in isoform detection

Antibody Incubation:
Begin with a 1:500 dilution and extend the primary antibody incubation to overnight at 4°C to maximize sensitivity for potentially lower-abundance isoforms .

Detection System:
Employ a high-sensitivity chemiluminescent detection system with extended exposure times to capture potential differences in expression levels between the isoforms.

A methodical approach to optimization will ensure comprehensive detection of all ATRAID isoforms, providing more complete insights into the protein's expression patterns across different experimental conditions.

What experimental controls are essential when using ATRAID antibody for studying cell cycle regulation?

When investigating ATRAID's role in cell cycle regulation, particularly its involvement in inducing cell cycle arrest via CCND1 inhibition within the ATRA signaling pathway, several critical controls must be incorporated:

Positive Controls:

• Include known ATRAID-expressing cell lines (such as HEK-293) as positive controls for antibody functionality

• Use samples with confirmed cell cycle arrest phenotypes (serum-starved cells) as comparative controls

Negative Controls:

• ATRAID knockdown/knockout samples using siRNA or CRISPR-Cas9 to confirm antibody specificity

• Secondary antibody-only controls to assess non-specific binding

• Isotype controls to evaluate potential background signal

Functional Controls:

• Parallel analysis of CCND1 expression levels to correlate with ATRAID expression

• Cell cycle synchronization experiments with FACS analysis to precisely determine the cell cycle stage affected by ATRAID

• Treatment with and without ATRA to examine pathway-specific effects on ATRAID function

• Time-course experiments to capture dynamic changes in ATRAID expression during cell cycle progression

Validation Controls:

• Use of multiple antibodies targeting different ATRAID epitopes to confirm observed expression patterns

• Correlation of protein expression with mRNA levels through parallel qRT-PCR analysis

• Subcellular fractionation to confirm the anticipated localization of ATRAID during cell cycle regulation

How can the ATRAID antibody be used to study the role of ATRAID in osteoblast differentiation?

Investigating ATRAID's function in osteoblast differentiation and terminal mineralization requires specialized experimental approaches utilizing the ATRAID antibody:

1. Temporal Expression Analysis:
Track ATRAID protein expression throughout the differentiation process of osteoblast precursor cells (e.g., MC3T3-E1 cells or primary mesenchymal stem cells) using Western blot with the ATRAID antibody at multiple time points (days 0, 3, 7, 14, 21). This temporal mapping can reveal critical windows when ATRAID expression correlates with key differentiation events .

2. Immunocytochemistry/Immunofluorescence:
While not specifically validated in the product information, the ATRAID antibody could potentially be optimized for immunofluorescence staining to:

• Visualize subcellular localization changes during differentiation

• Perform co-localization studies with osteoblast markers (RUNX2, OSX, OCN)

• Compare expression patterns between differentiating and terminally differentiated osteoblasts

3. Functional Studies Combined with Immunodetection:

• Perform ATRAID knockdown/overexpression experiments followed by Western blot analysis to correlate protein levels with differentiation markers

• Use the antibody to monitor ATRAID levels after treatment with differentiation-promoting factors (BMP-2, vitamin D, etc.)

• Combine ATRAID detection with mineralization assays (Alizarin Red S staining) to correlate protein expression with functional outcomes

4. Isoform-Specific Analysis:
Leverage the antibody's ability to detect all three isoforms to determine whether specific isoforms predominate during different stages of osteoblast differentiation:

• Use higher-resolution gel systems to clearly separate the isoforms

• Quantify the relative abundance of each isoform throughout the differentiation timeline

• Correlate isoform expression patterns with differentiation markers

5. Mechanistic Studies:

• Use immunoprecipitation (IP) with the ATRAID antibody followed by mass spectrometry to identify binding partners specific to osteoblast differentiation

• Perform chromatin immunoprecipitation (ChIP) assays following IP to identify potential DNA binding sites if ATRAID functions as a transcriptional regulator

These methodological approaches utilizing the ATRAID antibody can provide comprehensive insights into how ATRAID contributes to the complex process of osteoblast differentiation and mineralization.

What are best practices for validating ATRAID antibody specificity in experimental systems?

Thorough validation of ATRAID antibody specificity is critical for ensuring reliable experimental results. Researchers should implement the following best practices:

1. Genetic Validation Approaches:

• CRISPR-Cas9 knockout: Generate ATRAID knockout cell lines and confirm the absence of bands at the expected molecular weights

• siRNA/shRNA knockdown: Demonstrate reduced signal intensity proportional to knockdown efficiency

• Overexpression: Show increased signal intensity in cells transfected with ATRAID expression vectors

• Compare knockdown effects across multiple cell types to ensure consistent specificity

2. Peptide Competition Assays:

• Pre-incubate the antibody with excess immunizing peptide (if available) or recombinant ATRAID protein

• Run parallel Western blots with competed and non-competed antibody

• Specific bands should be significantly reduced or eliminated in the competed sample

3. Multi-Antibody Validation:

• Compare detection patterns with antibodies targeting different ATRAID epitopes

• Consistent detection of the same molecular weight bands across antibodies increases confidence in specificity

4. Cross-Species Reactivity Assessment:

• Test the antibody across samples from different species with known sequence homology

• Expected cross-reactivity with mouse samples has been confirmed, which can serve as a reference point

• Unexpected cross-reactivity may indicate potential specificity issues

5. Correlation with Other Detection Methods:

• Compare protein detection with mRNA expression (qRT-PCR)

• Conduct parallel mass spectrometry analysis to confirm protein identity

• Use fluorescent protein fusion constructs (ATRAID-GFP) to compare with antibody detection patterns

6. Lot-to-Lot Validation:

• Test new antibody lots against previously validated lots to ensure consistent detection patterns

• Maintain reference samples (e.g., HEK-293 lysates) for comparative validation across experiments

How can active learning approaches improve ATRAID antibody-based research methodologies?

Active learning strategies, similar to those employed in antibody-antigen binding research, can significantly enhance the efficiency and effectiveness of ATRAID antibody-based investigations:

1. Experimental Design Optimization:
Instead of exhaustively testing all possible experimental conditions, researchers can employ active learning to intelligently select the most informative experiments to perform first. For ATRAID antibody research, this might involve:

• Strategically selecting a diverse array of cell types based on sequence variation in the ATRAID gene

• Prioritizing testing conditions that maximize information gain about antibody specificity and sensitivity

• Using computational models to predict optimal antibody dilutions and incubation conditions

2. Sampling Strategy Implementation:
When studying ATRAID across multiple tissue types or experimental conditions, rather than random sampling, implement strategies such as:

• Hamming Average Distance method to select maximally diverse samples (shown to reduce experimental iterations by up to 35%)

• Gradient-Based uncertainty approaches to identify boundary cases where ATRAID detection may be challenging

• Query-by-Committee methods to determine which samples would be most informative for improving detection protocols

3. Iterative Refinement Process:
Apply an iterative approach to protocol optimization:

• Begin with a small set of diverse conditions for antibody validation

• Use results to train a predictive model for antibody performance

• Let the model suggest the next most informative experiments to perform

• Update the model with new data and repeat

• Continue until reaching desired performance metrics

4. Application to Multi-Isoform Detection:
For optimizing detection of all three ATRAID isoforms:

• Use receiver operating characteristic (ROC) area under curve (AUC) metrics to quantitatively assess detection quality across different protocol adjustments

• Apply active learning to identify the minimal set of experimental conditions needed to reliably detect all isoforms

• Reduce redundant experiments by focusing on conditions that highlight differences between isoforms

5. Computational Resource Integration:
Leverage computational tools to enhance active learning approaches:

• Simulate antibody binding characteristics using known protein structures

• Predict optimal experimental conditions based on physicochemical properties

• Integrate published data on similar antibodies to inform experimental design

Implementing these active learning strategies can significantly reduce the experimental resources required for optimizing ATRAID antibody protocols while improving research outcomes through more systematic and information-driven experimental design.

What storage and handling procedures will maximize ATRAID antibody performance?

Proper storage and handling of the ATRAID antibody are crucial for maintaining its performance and extending its usable lifespan:

Storage Conditions:
The ATRAID antibody (25548-1-AP) should be stored at -20°C, where it remains stable for one year after shipment. The product is provided in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, which helps maintain stability during freeze-thaw cycles .

• Preparing 10-20μL aliquots in sterile microcentrifuge tubes

• Quick-freezing aliquots using a dry ice/ethanol bath rather than placing directly in a freezer

• Maintaining records of freeze-thaw cycles for each aliquot

Freeze-Thaw Management:
While the glycerol in the storage buffer provides some protection, minimize freeze-thaw cycles by:

• Thawing the antibody on ice rather than at room temperature

• Returning to -20°C promptly after use

• Using sterile technique when handling to prevent contamination

Working Dilution Stability:
When preparing working dilutions:

• Store at 4°C for short-term use (up to 1 week)

• Add preservatives like sodium azide (0.02%) to working dilutions

• For dilutions intended for use beyond 1 week, consider adding protein carriers (1-5% BSA)

Temperature Sensitivity Considerations:

• Avoid prolonged exposure to room temperature

• Transport on ice when moving between laboratory areas

• Never heat the antibody solution

Contamination Prevention:

• Use only sterile pipette tips and containers

• Work in a clean environment to prevent microbial contamination

• Consider adding antimicrobial agents to working solutions

Adhering to these storage and handling practices will help ensure consistent performance of the ATRAID antibody throughout its expected shelf life, leading to more reproducible experimental results.

What are the comparative advantages of using ATRAID antibody in Western Blot versus ELISA applications?

Understanding the relative strengths of different applications can help researchers select the most appropriate method for their specific research questions regarding ATRAID:

Western Blot Advantages:

ELISA Advantages:

Application Selection Guidelines:

• Choose Western Blot when:

  • Isoform identification is critical

  • Sample purity is uncertain

  • Protein size confirmation is needed

  • Post-translational modifications are being investigated

• Choose ELISA when:

  • Precise quantification is required

  • Processing numerous samples simultaneously

  • Working with limited sample volumes

  • Standardized comparison across multiple experimental conditions is needed

Both applications have been validated for the ATRAID antibody (25548-1-AP) , providing researchers flexibility in experimental design based on their specific research requirements and available resources.

What troubleshooting approaches should be applied when ATRAID antibody produces unexpected results?

When encountering unexpected results with the ATRAID antibody, a systematic troubleshooting approach will help identify and resolve technical issues:

1. No Signal or Weak Signal:

2. Multiple Unexpected Bands:

3. Inconsistent Results Between Experiments:

4. Unexpected Molecular Weight:

5. High Background:

Systematic application of these troubleshooting strategies will help resolve technical issues and lead to more consistent and reliable results when working with the ATRAID antibody.

How might ATRAID antibody research contribute to understanding bone development disorders?

Given ATRAID's established role in promoting osteoblast differentiation and terminal mineralization, the ATRAID antibody provides a valuable tool for investigating various bone development disorders:

1. Potential Research Applications in Osteogenesis Imperfecta:

• Compare ATRAID expression patterns between normal and OI patient samples using Western blot

• Investigate whether specific ATRAID isoforms correlate with disease severity

• Explore potential compensatory mechanisms involving ATRAID in response to collagen mutations

• Examine ATRAID's interaction with BMP signaling pathways frequently disrupted in bone disorders

2. Investigation of Age-related Bone Loss:

• Track changes in ATRAID expression during aging using the antibody in young versus aged bone samples

• Correlate ATRAID levels with markers of osteoblast activity in age-matched samples

• Determine whether ATRAID expression changes precede clinical manifestations of osteoporosis

• Evaluate therapeutic interventions aimed at modulating ATRAID expression or function

3. Methodological Approaches for Developmental Studies:

• Apply the antibody in immunohistochemistry of developing bone tissue (with appropriate validation)

• Use time-course analysis during embryonic development to map ATRAID expression patterns

• Correlate protein expression with mineralization patterns during critical developmental windows

• Implement tissue-specific knockdown studies followed by antibody-based detection of compensatory mechanisms

4. Translational Research Potential:

• Screen compounds for their ability to modulate ATRAID expression in osteoblast precursors

• Develop high-throughput assays using ATRAID detection as a surrogate marker for osteoblast differentiation

• Evaluate ATRAID as a potential biomarker for bone formation capacity in personalized medicine approaches

• Investigate ATRAID's involvement in fracture healing and bone regeneration processes

By leveraging the ATRAID antibody's ability to detect multiple isoforms across human and mouse samples, researchers can develop deeper insights into both normal bone development and pathological conditions, potentially identifying novel therapeutic targets or diagnostic approaches for bone disorders.

How can researchers apply active learning principles to optimize ATRAID antibody experimental design?

Active learning methodologies can significantly enhance experimental efficiency when working with ATRAID antibody. These approaches allow researchers to maximize information gain while minimizing resource expenditure:

1. Experimental Condition Optimization Framework:

2. Implementation Methodology:

• Initial Exploration Phase:

  • Begin with small-scale experiments across diverse conditions

  • Use standard positive controls (HEK-293, mouse brain tissue) as anchoring data points

  • Collect quantitative performance metrics (signal-to-noise ratio, detection limit)

• Model Development Phase:

  • Build predictive models of antibody performance based on initial data

  • Identify variables most strongly affecting antibody performance

  • Develop optimization functions that balance information gain with resource cost

• Iterative Refinement Phase:

  • Let models suggest next most informative experiments

  • Perform selected experiments and measure outcomes

  • Update models with new data points

  • Repeat until performance reaches desired threshold

3. Application to Specific ATRAID Research Questions:

4. Practical Integration Steps:

• Develop a standardized scoring system for experimental outcomes

• Create a database of experimental conditions and corresponding results

• Implement computational tools to analyze patterns and suggest next experiments

• Establish clear stopping criteria based on performance thresholds

• Document the active learning process for transparency and reproducibility

By implementing these active learning principles, researchers can achieve up to 35% reduction in required experimental iterations while maintaining comparable accuracy to exhaustive testing approaches , significantly accelerating ATRAID-focused research while conserving valuable resources.

What potential roles might ATRAID play in cancer research, and how can the antibody facilitate these investigations?

ATRAID's established function in cell cycle regulation through CCND1 inhibition suggests important potential roles in cancer research that can be investigated using the ATRAID antibody:

1. Expression Analysis in Cancer Tissues:

The ATRAID antibody can be utilized to conduct comprehensive expression analyses across various cancer types:

• Compare ATRAID expression between matched tumor and normal tissues via Western blot

• Develop tissue microarray analyses to correlate ATRAID levels with clinical outcomes

• Investigate whether specific ATRAID isoforms predominate in particular cancer subtypes

• Assess ATRAID as a potential prognostic or predictive biomarker

2. Mechanistic Studies in Cancer Signaling:

3. Experimental Methodology for Cancer Research:

• Cell Line Screening Approach:

  • Use Western blot with ATRAID antibody to screen diverse cancer cell line panels

  • Correlate ATRAID expression with established cancer hallmarks

  • Identify model systems with altered ATRAID expression for functional studies

• Functional Intervention Studies:

  • Perform knockdown/overexpression of ATRAID followed by phenotypic assays

  • Monitor expression changes after treatment with various chemotherapeutics

  • Use the antibody to validate successful genetic manipulation

• Clinical Correlation Studies:

  • Develop immunohistochemistry protocols using the ATRAID antibody

  • Create scoring systems for ATRAID expression in tumor samples

  • Correlate with patient outcomes and treatment responses

4. Potential Therapeutic Implications:

• Screen for compounds that modulate ATRAID expression or function

• Investigate ATRAID as a potential therapeutic target in cancers with dysregulated cell cycle

• Examine ATRAID's role in response to differentiation-inducing therapies

• Explore combination approaches targeting ATRAID-related pathways

The ATRAID antibody's ability to detect multiple isoforms and its validated use in both human and mouse samples makes it particularly valuable for translational cancer research, enabling investigations from basic mechanistic studies through preclinical models to potential clinical applications.

What considerations are important when adapting ATRAID antibody protocols for co-immunoprecipitation studies?

Co-immunoprecipitation (Co-IP) is a powerful technique for investigating protein-protein interactions that could elucidate ATRAID's functional partners. While the ATRAID antibody (25548-1-AP) has been primarily validated for Western blot and ELISA applications, researchers can adapt it for Co-IP studies with the following considerations:

1. Antibody Suitability Assessment:

2. Protocol Optimization Recommendations:

• Antibody Concentration Determination:

  • Begin with higher concentration than WB (typically 2-5 μg per sample)

  • Perform titration experiments to identify optimal antibody-to-lysate ratio

  • Compare results with IgG control to assess specificity

• Lysis Buffer Selection:

  • Start with non-denaturing buffers (NP-40, Triton X-100) to preserve protein interactions

  • Include protease/phosphatase inhibitors to prevent degradation

  • Adjust salt concentration to balance specificity with interaction preservation

  • Consider additives like EDTA or EGTA based on interaction dependencies

• Bead Selection and Handling:

  • Test both Protein A and Protein G beads (Protein A generally works well with rabbit antibodies)

  • Pre-clear lysates to reduce non-specific binding

  • Optimize antibody-bead incubation time (typically 1-4 hours or overnight)

  • Determine optimal washing stringency to maintain specific interactions

3. Validation and Controls Framework:

4. Interaction Analysis Strategy:

• Primary IP with ATRAID antibody followed by Western blot for suspected interaction partners

• Mass spectrometry analysis of co-immunoprecipitated proteins for unbiased discovery

• Validation of identified interactions through reciprocal IP and functional studies

• Comparison of interactomes across different cell types and experimental conditions

By carefully adapting the ATRAID antibody for Co-IP applications using these methodological considerations, researchers can gain valuable insights into ATRAID's protein interaction network, further elucidating its cellular functions in osteoblast differentiation and cell cycle regulation.

How can bi-specific antibody technologies be leveraged to advance ATRAID functional research?

While the current ATRAID antibody (25548-1-AP) is a conventional antibody, emerging bi-specific antibody technologies offer innovative approaches for investigating ATRAID function. These technologies could be adapted for ATRAID research in the following ways:

1. Conceptual Framework for Bi-specific Applications:

Bi-specific antibodies contain two distinct binding domains that simultaneously target different epitopes or antigens. For ATRAID research, this technology could enable:

• Simultaneous detection of ATRAID and interaction partners

• Targeted manipulation of ATRAID in specific cellular compartments

• Enhanced sensitivity for detecting low-abundance ATRAID isoforms

• Novel therapeutic approaches targeting ATRAID-related pathways

2. Potential Research Applications:

3. Implementation Strategy for Researchers:

• Design Considerations:

  • Select optimal epitopes on ATRAID that don't interfere with protein function

  • Choose compatible secondary targets based on research questions

  • Consider format (tandem scFv, DVD-Ig, CrossMAb) based on specific application

  • Evaluate orientation effects on binding efficiency and specificity

• Validation Approach:

  • Compare binding characteristics with conventional ATRAID antibody

  • Assess potential steric hindrances affecting target recognition

  • Verify specificity using knockout/knockdown controls

  • Determine optimal working concentrations for different applications

• Application-Specific Optimization:

  • For imaging: Balance signal strength with background reduction

  • For functional studies: Minimize interference with normal protein activity

  • For therapeutic development: Evaluate on-target/off-target effects

  • For quantitative analysis: Establish standard curves with recombinant proteins

4. Advanced Experimental Concepts:

• ATRAID-T Cell Engagers: Mimicking therapeutic bi-specifics to study ATRAID in immune modulation

• Intracellular Bi-specifics: Using cell-penetrating domains to target intracellular ATRAID

• Conformation-Specific Recognition: Developing bi-specifics that recognize particular ATRAID structural states

• Degradation-Targeting Bi-specifics: Creating PROTAC-like molecules for selective ATRAID degradation

While development of bi-specific antibodies requires specialized expertise, collaborations with antibody engineering laboratories could provide ATRAID researchers with these advanced tools, opening new avenues for investigating ATRAID's complex roles in cell differentiation and cycle regulation .